[Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma]. [electronic resource]
Producer: 20090114Description: 1536-40 p. digitalISSN:- 0485-1439
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20 -- analysis
- Antineoplastic Agents -- therapeutic use
- Biomarkers, Tumor -- analysis
- Cyclin D1 -- analysis
- Female
- Gene Expression
- Humans
- Middle Aged
- Multiple Myeloma -- diagnosis
- Rituximab
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; English Abstract; Journal Article
There are no comments on this title.
Log in to your account to post a comment.